

## **Oral Anticoagulant Use by Emergency Medical Services Patients in the United States**

February 25, 2023

<b><u>Name</u></b>	<b><u>Affiliation</u></b>	<b><u>Email</u></b>
Henry Wang, MD	The Ohio State University Department of Emergency Medicine	<a href="mailto:henry.wang@osumc.edu">henry.wang@osumc.edu</a>
Mengda Yu, MSPH	The Ohio State University Department of Biomedical Informatics	<a href="mailto:Mengda.yu@osumc.edu">Mengda.yu@osumc.edu</a>
Ching Min Chu	The Ohio State University Department of Emergency Medicine	<a href="mailto:Chingmin.chu@osumc.edu">Chingmin.chu@osumc.edu</a>
Travis P. Sharkey-Toppen, MD, PhD	The Ohio State University Department of Emergency Medicine	<a href="mailto:travis.sharkey-toppen@osumc.edu">travis.sharkey-toppen@osumc.edu</a>
J. Madison Hyer, MS	The Ohio State University Department of Biomedical Informatics	<a href="mailto:madison.hyer@osumc.edu">madison.hyer@osumc.edu</a>
Michelle Nassal, MD, PhD	The Ohio State University Department of Emergency Medicine	<a href="mailto:Michelle.Nassal@osumc.edu">Michelle.Nassal@osumc.edu</a>
Alix Delamare, MD	The Ohio State University Department of Emergency Medicine	<a href="mailto:alix.delamare@gmail.com">alix.delamare@gmail.com</a>
Joanthon Powell,	The Ohio State University Department of Emergency Medicine	<a href="mailto:jonathan.powell@osumc.edu">jonathan.powell@osumc.edu</a>
Lai Wei, PhD	The Ohio State University Department of Biomedical Informatics	<a href="mailto:lai.wei@osumc.edu">lai.wei@osumc.edu</a>
Ashish Panchal, MD, PhD	The Ohio State University Department of Emergency Medicine	<a href="mailto:Ashish.Panchal@osumc.edu">Ashish.Panchal@osumc.edu</a>

### **Contact:**

Henry E. Wang, MD, MS  
Professor and Vice Chair for Research  
Department of Emergency Medicine  
The Ohio State University  
376 W. 10th Ave  
789 Prior Hall  
Columbus, OH 43210  
[Henry.wang@osumc.edu](mailto:Henry.wang@osumc.edu)  
205-410-1267

**Word Count:** 2,007 words

**Keywords:** Emergency Medical Services, anticoagulants, hemorrhage, medications

Oral Anticoagulant Use in EMS Patients  
Page 2 of 24

**Presented at:** National Association of EMS Physicians Annual Meeting, Tampa, Florida, January 2023.

### **Acknowledgements**

The content derived from this Data Set remains the property of ESO Solutions, Inc. ESO is not responsible for any claims arising from works based on the original data, text, tables, or figures. The authors wish to express their appreciation to ESO for its assistance with the data.

Oral Anticoagulant Use in EMS Patients  
Page 3 of 24

**ABSTRACT**

**OBJECTIVE:** Oral anticoagulant (OAC) use raises the risk of death in life-threatening conditions such as hemorrhagic stroke, trauma and traumatic brain injury. We sought to describe the national characteristics of Emergency Medical Services patients with a history of OAC use.

**METHODS:** We used prehospital electronic medical record data from 2018-2020 from the ESO Data Collaborative. We included adults (age $\geq$ 18 years) receiving 911 EMS care. OAC use included warfarin, dabigatran, rivaroxaban and apixaban. We determined the incidence of EMS calls by OAC users as well as their variation by EMS agency. We compared EMS call, patient, and response characteristics between OAC and non-OAC users, including primary impressions and hospital diagnoses.

**RESULTS:** There were 16,244,550 adult 911 EMS events, including 906,575 by OAC users (56 per 1,000 911 events). Compared with non-OAC users, OAC users were more likely to be older (73.6 vs. 56.9 years), white (78.0% vs. 51.4%) and non-Hispanic (84.5% vs. 78.0%). Incidents involving OAC users were more likely at nursing homes, rehabilitation or long-term care facilities (17.0% vs. 9.2%) but less likely to involve trauma (14.7% vs. 18.1%) or cardiac arrest (1.2% vs. 1.4%). Among OAC users, the most common EMS primary clinical impressions were chest pain (7.4%), altered mental status (7.3%), injury (6.5%), abdominal pain (4.3%), and brain injury (2.8%).

**CONCLUSIONS:** In this national series of prehospital events, 1 in 18 adult EMS encounters involved OAC users. These results provide key perspectives on the presentation of the OAC users in EMS care.

**Abstract word count:** 244

## **INTRODUCTION**

### *Background*

Life-threatening hemorrhage such as traumatic brain injury, hemorrhagic stroke, gastrointestinal bleeding or vascular or visceral injury from blunt or penetrating trauma, is among the most important time-critical conditions treated by prehospital Emergency Medical Services (EMS).<sup>1,2</sup> Common EMS interventions for life-threatening bleeding include direct hemorrhage control, tourniquet application, administration of intravenous fluids and vasopressors. Select EMS units are also able to treat hemorrhage with blood products such as red blood cells, whole blood and plasma.<sup>3-5</sup>

### *Importance*

Oral anticoagulants such as warfarin and direct oral anticoagulants (OAC - dabigatran, rivaroxaban, and apixaban) are widely used in the outpatient setting for treating or preventing a range of medical conditions. For example, OACs may be used to prevent strokes in patients with atrial fibrillation or after prosthetic heart valve replacement. OACs are also commonly used to treat or prevent thromboembolism.<sup>6</sup> Oral anticoagulant use is increasing internationally.<sup>6-11</sup> A major pitfall of OACs is that their use increases the risk of serious bleeding, including life-threatening hemorrhage.<sup>6</sup> Given EMS's role in the emergent treatment of hemorrhage, knowledge of a patient's OAC use history is essential, potentially influencing prehospital care and outcomes. Despite the prevalence of OAC use, there are no broad descriptions of OAC use history among patients receiving EMS care.

### *Goals of this Investigation*

Leveraging a large-scale EMS electronic health record system, we sought to describe the characteristics and course of EMS patients with a history of oral anticoagulant (OAC) use.

## **METHODS**

### *Study Design and Setting*

We analyzed data from the ESO Data Collaborative (Austin, TX). This analysis was approved by the Ohio State University Office of Responsible Research Practices.

The ESO Data Collaborative (Austin, TX) is one of the largest out-of-hospital electronic health record systems in the United States. The software product collects clinical information for the EMS encounter, including event characteristics, patient demographics, clinical signs and symptoms, interventions, vital signs, and outcomes. The software contains data validation (forcing) options to require or constrain user entries for select data elements. The current software follows the National EMS Information System (NEMESIS) version 3 standard and the associated data definitions.<sup>12</sup> More than 2,000 EMS agencies use the ESO electronic health record software system.

The ESO Data Set is a repository of clinical data from EMS agencies that agreed to providing de-identified data for research and benchmarking. The data have been used in a wide range of research studies.<sup>13-16</sup> In select communities, these EMS records are linked with hospital outcomes data through a proprietary bi-directional Healthcare Data Exchange (HDE) system. Among participating hospitals and EMS agencies, hospital data elements (including ICD-10 diagnosis codes and dispositions) are linked with the prehospital record using HL7 messaging.

### *Selection of Participants*

We included all adult patients ( $\geq 18$  years) receiving “911” EMS care with a reported history of oral anticoagulant use. EMS providers reported medication history as obtained during the course of clinical

## Oral Anticoagulant Use in EMS Patients

Page 6 of 24

care. OAC used included the reported use of warfarin (Coumadin®), dabigatran (Pradaxa®), rivaroxaban (Xarelto®), and apixaban (Eliquis®). While not part of the primary analysis, we also identified instances of reported injected anticoagulants, including heparin, enoxaparin (Lovenox®), dalteparin (Fragmin®), Fondaparinux (Arixtra®), and Edoxaban (Savaysa®). We included only medications reported as part of the patient's medical history, not medications administered during EMS care. We did not study other oral medications that may potentiate bleeding such as such as antiplatelet agents (-e.g., aspirin or clopidogrel).

### *Outcomes*

We focused on clinical variables plausibly associated with or influenced by a history of OAC use. Variables of primary interest included patient characteristics (age, sex, race, ethnicity), incident characteristics (location type, medical vs. trauma, cardiac arrest, census region). We also determined the primary clinical impression reported by EMS providers; we grouped the impressions according to ICD-10 categories as implemented in the NEMESIS v.3 system.<sup>17</sup> We also identified subcategories within each primary impression major category. For the subset of EMS events linked to hospital data, we identified the primary hospital discharge diagnosis, grouping according to ICD-10 disease category.

### *Data Analysis*

We determined the number and incidence of adult 911 responses with a reported patient history of OAC use. Using univariate logistic regression, we compared patient, incident and care characteristics between OAC vs non-OAC users. We compared EMS primary clinical impressions between events involving OAC and non-OAC users. Among cases linked to hospital data, we assessed differences in primary discharge diagnoses between OAC and non-OAC users.

## Oral Anticoagulant Use in EMS Patients

Page 7 of 24

### **RESULTS**

During the study period (2018-2020) there were 16.2 million 911 responses. A history of patient OAC use was reported for 906,575 911 events (55.8 per 1,000 911 events (95% CI 55.7-55.9%)). (Figure 1) The most commonly reported OACs were apixaban (46.0%), warfarin (34.8%), rivaboxarin (17.5%) and dabigatran (2.4%). (Table 1) The use of other injectable anticoagulants was reported for a smaller number of patients. When stratified by EMS agency, the median incidence of OAC use was 54 per 1,000 911 responses (95% CI: 52, 56, min 0, max 500).

Compared with other patients, OAC users were more likely to be older and female. (Table 2) Whites and non-Hispanics were more likely to use OACs. Patient OAC use history was more likely for calls in nursing rehabilitation and long-term care facilities, and less likely for calls in public locations. Compared with medical patients, patients with trauma-associated conditions were less likely to report OAC use. However, OAC use was more common among patients with mixed medical/trauma conditions. OAC use was twice as likely among patients presenting with cardiac arrest. OAC use was least likely among EMS events in the Midwest census region.

OAC use history was most common among patients with a reported clinical impression involving cardiovascular, infectious or respiratory conditions. (Table 3) Specific primary clinical impressions strongly associated with OAC use history included acute coronary syndromes, arrhythmias, heart failure, gastrointestinal bleeding, hemorrhaging, urinary tract infection, ear, nose and throat problems, pulmonary embolism, and pulmonary hypertension. (Appendix 1) Of note, neurologic conditions including intracranial hemorrhage, vertigo, strokes and transient ischemic attacks and visual disturbances were associated with OAC use. (Appendix 1)

## Oral Anticoagulant Use in EMS Patients

Page 8 of 24

Among the 16.2 million adult 911 events, linkage to hospital data was available for 621,158 patients (3.8%). (Table 4) Hospital discharge diagnosis categories most strongly associated with patient OAC use history included D50-D89 (Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism), I00-I99 (diseases of the circulatory system), and L00-L99 (diseases of the skin and subcutaneous tissue).



## **LIMITATIONS**

OAC use may have been underestimated. EMS providers likely recorded OAC use based upon clinical data sources such as patient and family reports. It is unclear if reports may have been based upon medication administration or pharmacy records. Medication records may also not be available for patients who were unconscious or exhibited altered mentation. We identified OAC use but not the reasons for their use. We also could not identify the dosages of OACs used by patients. We identified patterns of OAC use and their associations with select conditions; we did not evaluate associations between OAC use and patient outcomes. The latter varies by underlying disease process and requires risk adjustment, which is not standardized for linked EMS-hospital data. While we were able to identify hospital conditions through discharge diagnoses, we were not able to identify the specific pathologic conditions experienced by OAC patients. We did not apply multivariate regression to identify predictors of OAC given the large number of variables and uncertain statistical power. We did not study parenteral anticoagulants nor other agents that may potentiate bleeding such as such as antiplatelet agents.

## **DISCUSSION**

The history of OAC use is a critical risk factor in life-threatening hemorrhagic and neurologic emergencies. Our study offers important information on the incidence and characteristics of OAC users receiving EMS care. In this national series, 1 of every 18 adult EMS responses involved a patient with history of OAC use. In some EMS agencies the prevalence of OAC use was even higher. As expected, OAC use was common in certain patients with high-risk conditions such as cardiovascular and respiratory diseases, and central neurologic emergencies. OAC use was also strongly associated with EMS responses at nursing, rehabilitation and long-term facilities. These observations highlight the prevalence of OAC use among EMS patients and are particularly important given the increasing prevalence of OAC use internationally.<sup>6-8,10,11</sup>

The knowledge of a patient's history of OAC use has extremely important implications for EMS care. OAC use may directly amplify the severity and risk of critical conditions, such as hemorrhagic stroke, traumatic brain injury, or gastrointestinal or extremity bleeding.<sup>6,18</sup> In the setting of acute life-threatening bleeding, knowledge of a patient's OAC use history may prompt the hospital use of rescue therapies such as blood products (-eg, plasma or red cells), procoagulants (-eg, tranexamic acid, vitamin K, prothrombin complex concentrate) or direct OAC-specific reversal agents (-eg, andexanet, idarucizumab).<sup>6,19</sup> Because of the potential for rapid deterioration of patients with life-threatening hemorrhage, even the early accurate identification of OAC use history can have important downstream benefits.<sup>20</sup> The identification of OAC use history may prompt earlier notification to receiving hospitals or transportation to specialty care centers; for example, direct transportation to a trauma center.<sup>20</sup> Nishijima, et al. found that the addition of OAC use to trauma triaging criteria improved the sensitivity for detection of intracranial hemorrhage and death.<sup>2</sup> Novel technologies such as mobile stroke units may also be leveraged to accelerate identification or exclusion of intracranial hemorrhage in high-risk OAC users.<sup>21,22</sup> In certain

## Oral Anticoagulant Use in EMS Patients

Page **11** of **24**

settings, prehospital administration of procoagulants or OAC-reversal agents may be feasible and appropriate.

Our observations extend upon prior studies. In a retrospective analysis of 2,110 EMS responses for older (age  $\geq 55$ ) persons with head injury, 28% were identified with a history of OAC use.<sup>2</sup> We found that while many EMS calls for OAC users involved a primary condition of trauma, the majority of events involved non-traumatic emergencies. Prior studies highlight the increasing prevalence of OAC use among older adults and nursing home patients.<sup>9,23,24</sup> Our study affirms these observations, finding that OAC use was more likely among EMS responses at nursing, rehabilitation and long-term care facilities. Our study spotlights the broader systemwide prevalence of OAC use. The latter approach is important for several reasons. First, we were able to identify OAC use in an EMS population with diverse emergency conditions. Secondly, we able to identify individuals with baseline OAC use - not just those with confirmed hemorrhage.

We were also able to glean insights from the small proportion of patients linked to hospital data. The formation of inferences from linked prehospital/hospital data can be challenging due to the structure of discharge diagnosis coding taxonomies (the International Classification of Diseases) and the myriad medical conditions. We found that focus on key disease subsets was important in identifying hospital conditions associated with patient OAC use. For example, OAC use was not associated with the broad category of neurologic conditions. However, key subset conditions such as intracranial hemorrhage and stroke revealed strong associations with OAC use. The use of linked EMS/hospital data to assess OAC use with hospital outcomes will need careful analytic strategies and taxonomies to identify high OAC-risk conditions.

## Oral Anticoagulant Use in EMS Patients

Page 12 of 24

Our study highlights several important areas for future investigation. Nishijima, et al. found that EMS clinicians often do not accurately identify direct OAC use.<sup>1</sup> In this context, clinical decision rules may aid in identifying patient and call characteristics at higher risk for OAC use. Our observations highlight several plausible candidate variables such as older age, white race, cardiac arrest, or call locations. Given the wide range of OAC use, additional study is needed to distinguish EMS presentations at high risk for sequelae from hemorrhage. Lastly, geographic mapping of OAC users could be very insightful for system level preparation, identifying hotspots for deploying and positioning resources such as mobile stroke units, procoagulant medications, and novel OAC reversal agents. We observed that EMS calls with OAC users were more common in the Northeast census region, highlight the potential importance of national regional variations in OAC use.

In conclusion, in this national series 1 in 18 adult EMS encounters involved OAC users. While OAC use was common in high-risk populations, presentation with injury was less common. These results offer perspectives on the population of OAC patients receiving EMS care.

## **REFERENCES**

1. Nishijima DK, Gaona S, Waechter T, et al. Do EMS Providers Accurately Ascertain Anticoagulant and Antiplatelet Use in Older Adults with Head Trauma? Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors 2017;21:209-15.
2. Nishijima DK, Gaona SD, Waechter T, et al. Out-of-Hospital Triage of Older Adults With Head Injury: A Retrospective Study of the Effect of Adding "Anticoagulation or Antiplatelet Medication Use" as a Criterion. *Annals of emergency medicine* 2017;70:127-38 e6.
3. Sperry JL, Guyette FX, Brown JB, et al. Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. *New England Journal of Medicine* 2018;379:315-26.
4. Braverman MA, Smith A, Pokorny D, et al. Prehospital whole blood reduces early mortality in patients with hemorrhagic shock. *Transfusion* 2021;61 Suppl 1:S15-s21.
5. Crombie N, Doughty HA, Bishop JRB, et al. Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial. *The Lancet Haematology* 2022;9:e250-e61.
6. Chen A, Stecker E, B AW. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. *J Am Heart Assoc* 2020;9:e017559.
7. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory Oral Anticoagulant Use. *The American journal of medicine* 2015;128:1300-5 e2.
8. Lutsey PL, Walker RF, MacLehose RF, Alonso A, Adam TJ, Zakai NA. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017. *Res Pract Thromb Haemost* 2019;3:668-73.
9. Chen Q, Lapane K, Nunes AP, Tjia J, Hugunin J, Alcusky M. Prevalence and the factors associated with oral anticoagulant use among nursing home residents. *J Clin Pharm Ther* 2021;46:1714-28.
10. Colacci M, Tseng EK, Sacks CA, Fralick M. Oral Anticoagulant Utilization in the United States and United Kingdom. *J Gen Intern Med* 2020;35:2505-7.
11. Zapata-Wainberg G, Quintas S, Ximenez-Carrillo Rico A, et al. Epidemiology of Intracranial Hemorrhage Associated with Oral Anticoagulants in Spain: Trends in Anticoagulation Complications Registry - The TAC 2 Study. *Interv Neurol* 2018;7:284-95.
12. NEMESIS. (Accessed November 28, 2021, at <https://nemsis.org/>.)
13. Nwanne T, Jarvis J, Barton D, Donnelly JP, Wang HE. Advanced airway management success rates in a national cohort of emergency medical services agencies. *Resuscitation* 2020;146:43-9.
14. Wang HE, Donnelly JP, Barton D, Jarvis JL. Assessing Advanced Airway Management Performance in a National Cohort of Emergency Medical Services Agencies. *Annals of emergency medicine* 2018;71:597-607 e3.

## Oral Anticoagulant Use in EMS Patients

Page 14 of 24

15. Walter DC, Chan HK, Crowe RP, Osborn L, Jarvis J, Wang HE. Out-of-hospital, non-invasive, positive-pressure ventilation for acute dyspnea. *J Am Coll Emerg Physicians Open* 2021;2:e12542.
16. George TP, Chan HK, Crowe RP, et al. Clinical characteristics and course of out-of-hospital shock in a national emergency medical services cohort. *J Am Coll Emerg Physicians Open* 2020;1:432-9.
17. NEMSIS Technical Advisory Center. The Development of Defined Lists for Specific NEMSIS Elements
18. Probst MA, Gupta M, Hendey GW, et al. Prevalence of Intracranial Injury in Adult Patients With Blunt Head Trauma With and Without Anticoagulant or Antiplatelet Use. *Annals of emergency medicine* 2020;75:354-64.
19. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. *Journal of the American College of Cardiology* 2020;76:594-622.
20. Ashton C, Sammut-Powell C, Birleson E, Mayoh D, Sperrin M, Parry-Jones AR. Implementation of a prealert to improve in-hospital treatment of anticoagulant-associated strokes: analysis of a prehospital pathway change in a large UK centralised acute stroke system. *BMJ Open Qual* 2020;9.
21. Turc G, Hadziahmetovic M, Walter S, et al. Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management: A Systematic Review and Meta-analysis. *JAMA Neurol* 2022;79:281-90.
22. Lees KR. Does My District Need a Mobile Stroke Unit? *The New England journal of medicine* 2021;385:1043-4.
23. Alcusky M, Baek J, Tjia J, McManus DD, Lapane KL. Geographic Variation in Anticoagulant Use and Resident, Nursing Home, and County Characteristics Associated With Treatment Among US Nursing Home Residents. *J Am Med Dir Assoc* 2021;22:164-72 e9.
24. Alcusky M, McManus DD, Hume AL, Fisher M, Tjia J, Lapane KL. Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016. *J Am Heart Assoc* 2019;8:e012023.

Oral Anticoagulant Use in EMS Patients  
Page 15 of 24

**TABLE 1**

Oral and other anticoagulants reported by EMS patients. Only oral anticoagulants (OAC) were included in the primary analysis.

Characteristic	N (% of all 911 Events)
<b>Oral Anticoagulants (OAC)</b>	
Apixaban (Eliquis®)	416,843 (2.57)
Warfarin (Coumadin®)	315,481 (1.94)
Rivaboxarin (Xarelto®)	158,931 (0.98)
Dabigatran (Pradaxa®)	22,637 (0.14)
<b>Heparins and Factors Xa Inhibitors</b>	
Enoxaparin (Lovenox®)	33,624 (0.21)
Heparin	16,636 (0.10)
Dalteparin (Fragmin®)	8 (0.0)
Fondaparinux (Arixtra®)	1 (0.0)
Edoxaban (Savaysa®)	0 (0.0)
<b>Antiplatelet Agents</b>	
Clopidogrel (Plavix®)	469,211 (2.89)
Prasugrel (Effient)	7898 (0.05)
Ticagrelor (Brilinta)	25,898 (0.16)
Acetylsalicylic acid (Aspirin)	861,906 (5.31)

Oral Anticoagulant Use in EMS Patients  
Page 16 of 24

**TABLE 2**

Characteristics of EMS patients stratified by history of oral anticoagulant (OAC) use. OAC use defined as use of warfarin (coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). Odds ratios determined using univariate logistic regression.

Characteristic	OAC Use N= 906,575 (5.6%)	No OAC Use N=15,337,975 (94.4%)	Odds Ratio (95% CI) OAC vs no OAC
<b>Age (yrs) - Mean (SD)</b>	73.60 (14.44)	56.91 (21.15)	1.047 (1.047, 1.047)
<b>Age Group (y)</b>			
18-30	7,536 (0.8%)	2,290,499 (14.9%)	Reference
31-40	17,482 (1.9%)	1,800,160 (11.7%)	2.95 (2.87, 3.03)
41-50	36,877 (4.1%)	1,748,020 (11.4%)	6.40 (6.24, 6.56)
51-60	87,048 (9.6%)	2,358,358 (15.4%)	11.20 (10.94, 11.46)
61-70	161,712 (17.8%)	2,490,566 (16.2%)	19.70 (19.25, 20.16)
>70	595,920 (65.7%)	4,650,369 (30.3%)	38.87 (38.00, 39.77)
<b>Sex</b>			
Female	470,812 (51.9%)	7,885,062 (51.4%)	Reference
Male	428,773 (47.2%)	7,253,916 (47.3%)	0.99 (0.98, 0.99)
Unknown	95 (0.01%)	3,033 (0.02%)	0.53 (0.43, 0.65)
Missing	6,895 (0.8%)	195,964 (1.3%)	
<b>Race</b>			
White	706,991 (78.0%)	10,090,534 (65.8%)	Reference
American Indian or Alaska Native	1,019 (0.1%)	39,668 (0.3%)	0.37 (0.35, 0.39)
Asian	3,946 (0.4%)	125,022 (0.8%)	0.45 (0.44, 0.47)
Black or African American	119,872 (13.2%)	3,168,567 (20.7%)	0.540 (0.537, 0.543)
Native Hawaiian or Other Pacific Islander	828 (0.1%)	20,280 (0.1%)	0.58 (0.54, 0.63)
Other Race	15,591 (1.7%)	738,306 (4.8%)	0.30 (0.30, 0.31)
Unknown	3,723 (0.4%)	114,747 (0.8%)	0.46 (0.45, 0.48)
Missing	54,605 (6.0%)	1,040,851 (6.8%)	
<b>Ethnicity</b>			
Not Hispanic or Latino	765,913 (84.5%)	11,964,775 (78.0%)	Reference
Hispanic or Latino	24,423 (2.7%)	1,056,441 (6.9%)	0.361 (0.357, 0.366)
Missing	116,239 (12.8%)	2,316,759 (15.1%)	
<b>Location Type</b>			
Home/Private Residence	639,900 (70.6%)	9,033,950 (58.9%)	Reference
Doctor' Offices, Clinics and Other Healthcare Facilities	38,729 (4.3%)	588,563 (3.8%)	0.93 (0.92, 0.94)
Nursing, Rehabilitation and Long-Term Care Facilities	154,321 (17.0%)	1,409,324 (9.2%)	1.55 (1.54, 1.56)
Other	12,077 (1.3%)	484,384 (3.2%)	0.352 (0.346, 0.358)
Public Location	58,105 (6.4%)	3,652,213 (23.8%)	0.23 (0.22, 0.23)
Missing	3,570 (0.4%)	169,414 (1.1%)	
<b>Medical Trauma</b>			
Medical	727,877 (80.3%)	11,508,021 (75%)	Reference
Medical & Trauma	27,679 (3.1%)	379,595 (2.5%)	1.15 (1.14, 1.17)
Trauma	133,215 (14.7%)	2,778,524 (18.1%)	0.76 (0.75, 0.76)
Missing	17,804 (2%)	671,835 (4.4%)	
<b>Injured</b>			
No	734,366 (81%)	120,042,521 (78.5%)	Reference



Oral Anticoagulant Use in EMS Patients  
Page 17 of 24

Characteristic	OAC Use N= 906,575 (5.6%)	No OAC Use N=15,337,975 (94.4%)	Odds Ratio (95% CI) OAC vs no OAC
Yes	160,230 (17.7%)	3,059,377 (20%)	0.859 (0.854, 0.864)
Missing	11,979 (1.3%)	236,077 (1.5%)	
<b>Cardiac Arrest</b>			
No	5,790 (0.6%)	234,516 (1.5%)	Reference
Yes, After EMS Arrival	1,373 (0.2%)	27,547 (0.2%)	2.02 (1.90, 2.14)
Yes, Prior to EMS Arrival	9381 (1.0%)	184,315 (1.2%)	2.06 (1.99, 2.13)
Missing	890,031 (98.2%)	14,891,597 (97.1%)	
<b>Region</b>			
1 - Northeast	80,115 (8.8%)	854,862 (5.6%)	1.74 (1.72, 1.75)
2 - Midwest	193,636 (21.4%)	3,585,273 (23.4%)	Reference
3 - South	454,116 (50.1%)	8,075,588 (52.7%)	1.04 (1.04, 1.05)
4 - West	165,095 (18.2%)	2,447,426 (16%)	1.25 (1.24, 1.26)
Missing	13,613 (1.5%)	374,826 (2.4%)	

**TABLE 3**

EMS primary clinical impression, stratified by history of oral anticoagulant (OAC) use. Includes 906,575 OAC and 15,337,975 non-OAC patients. Detailed clinical impression subcategories presented in Appendix 1.

Primary Clinical Impression	OAC Use 906 575 (5.6%)	No OAC Use 15,337,975 (94.4%)	Odds Ratio (95% CI) OAC vs No OAC
1. Cardiovascular	131,315 (14.5%)	1,579,867 (10.3%)	1.475 (1.466, 1.44)
2. Gastrointestinal	69,888 (7.7%)	1,283,066 (8.4%)	0.915 (0.908, 0.922)
3. Endocrine and Electrolyte Abnormalities	14,885 (1.6%)	347,088 (2.3%)	0.72 (0.71, 0.73)
4. Infection	26,215 (2.9%)	311,193 (2.0%)	1.44 (1.42, 1.46)
5. Injury and Environmental Conditions	136,370 (15.0%)	2,458,143 (16.0%)	0.928 (0.922, 0.933)
6. Kidney/Genitourinary	12,244 (1.4%)	209,106 (1.4%)	0.99 (0.97, 1.01)
7. Neonatal	9 (0%)	99 (0%)	1.54 (0.78, 3.05)
8. Neurological	121,213 (13.4%)	2,151,632 (14.0%)	0.946 (0.940, 0.952)
9. Psychiatric	14,977 (1.7%)	864,445 (5.6%)	0.281 (0.277, 0.286)
10. Respiratory and Airway	116,216 (12.8%)	1,244,961 (8.1%)	1.67 (1.65, 1.68)
11. Toxicologic Exposures	7,209 (0.8%)	757,298 (4.9%)	0.154 (0.151, 0.158)
12. Other	244,563 (27.0%)	3,781,705 (24.7%)	1.129 (1.124, 1.134)
Missing	11,471 (1.3%)	349,372 (2.3%)	

**TABLE 4**

Primary hospital ICD-10 discharge diagnoses of EMS patients with a history of oral anticoagulant (OAC) use. Includes 621,158 of 16,244,550 (3.8%) EMS encounters successfully linked with hospital records.

ICD-10 Group	Description	OAC Use 64,344 (10.6%)	No OAC Use 541,770 (89.4%)	Odds Ratio (95% CI) OAC vs No OAC
---	No diagnosis	1,186 (1.8%)	13,465 (2.5%)	0.74 (0.69, 0.78)
A00–B99	Certain infectious and parasitic diseases	4,194 (6.5%)	35,536 (6.6%)	0.99 (0.96, 1.03)
C00–D48	Neoplasms	352 (0.6%)	3,828 (0.7%)	0.77 (0.69, 0.86)
D50–D89	Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	1,149 (1.8%)	6,407 (1.2%)	1.52 (1.43, 1.62)
E00–E90	Endocrine, nutritional and metabolic diseases	2,574 (4%)	28,226 (5.2%)	0.76 (0.73, 0.79)
F00–F99	Mental and behavioral disorders	508 (0.8%)	18,109 (3.3%)	0.23 (0.21, 0.25)
G00–G99	Diseases of the nervous system	1,573 (2.4%)	17,245 (3.2%)	0.76 (0.72, 0.80)
H00–H59	Diseases of the eye and adnexa	34 (0.1%)	363 (0.1%)	0.79 (0.56, 1.12)
H60–H95	Diseases of the ear and mastoid process	50 (0.1%)	473 (0.1%)	0.90 (0.67, 1.20)
I00–I99	Diseases of the circulatory system	13,062 (20.3%)	80,695 (14.9%)	1.46 (1.43, 1.49)
J00–J99	Diseases of the respiratory system	6,521 (10.1%)	54,480 (10.1%)	1.01 (0.98, 1.04)
K00–K93	Diseases of the digestive system	3,888 (6.0%)	34,223 (6.3%)	0.95 (0.92, 0.99)
L00–L99	Diseases of the skin and subcutaneous tissue	875 (1.4%)	6,005 (1.1%)	1.23 (1.15, 1.32)
M00–M99	Diseases of the musculoskeletal system and connective tissue	1,417 (2.2%)	10,697 (2.0%)	1.12 (1.06, 1.18)
N00–N99	Diseases of the genitourinary system	3,580 (5.6%)	26,259 (4.9%)	1.16 (1.12, 1.20)
O00–O99	Pregnancy, childbirth and the puerperium	9 (0%)	2,818 (0.5%)	0.03 (0.01, 0.05)
P00–P96	Certain conditions originating in the perinatal period	1 (0%)	22 (0%)	0.40 (0.06, 2.85)
Q00–Q99	Congenital malformations, deformations and chromosomal abnormalities	11 (0%)	121 (0%)	0.77 (0.41, 1.42)
R00–R99	Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	14,840 (23.1%)	115,965 (21.4%)	1.10 (1.08, 1.12)
S00–T98	Injury, poisoning and certain other consequences of external causes	5,802 (9.0%)	61,849 (11.4%)	0.77 (0.75, 0.79)
U00–U99	Other diagnoses	820 (1.3%)	8,909 (1.6%)	0.77 (0.72, 0.83)
V01–Y98	External causes of morbidity and mortality	1,229 (1.9%)	10,363 (1.9%)	1.00 (0.94, 1.06)
Z00–Z99	Factors influencing health status and contact with health services	669 (1.0%)	5,712 (1.1%)	0.99 (0.91, 1.07)

Event-Free Days in OHCA  
Page **20** of **24**

**FIGURE 1**

Study population.

**APPENDIX 1**

Detailed EMS primary clinical impression, stratified by history of oral anticoagulant (OAC) use. Includes 906, 575 OAC and 15, 337, 975 non-OAC.

EMS Primary Clinical Impression	OAC User 906,575 (5.6%)	Not OAC User 15,337,975 (94.4%)	OAC vs No OAC
<b>1. Cardiovascular</b>	<b>131,315 (14.5%)</b>	<b>1,579,867 (10.3%)</b>	<b>1.48 (1.47, 1.48)</b>
Acute Coronary Syndrome	66 (0%)	537 (0%)	2.08 (1.61, 2.69)
Angina	1,486 (0.2%)	19,346 (0.1%)	1.30 (1.23, 1.37)
Arrhythmia	25,394 (2.8%)	137,698 (0.9%)	3.18 (3.14, 3.23)
Cardiac Arrest	9,424 (1.0%)	183,593 (1.2%)	0.87 (0.85, 0.89)
Cardiac Tamponade	12 (0%)	89 (0%)	2.39 (1.32, 4.31)
Cardiac, Other	368 (0%)	3,167 (0%)	1.97 (1.77, 2.19)
Cardiogenic Shock	172 (0%)	2,280 (0%)	1.28 (1.09, 1.49)
Chest Pain; Nos	67,264 (7.4%)	927,386 (6.1%)	1.25 (1.24, 1.26)
Heart Failure	5,744 (0.6%)	28,736 (0.2%)	3.40 (3.30, 3.50)
Hypertension	7,583 (0.8%)	138,112 (0.9%)	0.93 (0.91, 0.95)
Hypotension	10,600 (1.2%)	96,034 (0.6%)	1.88 (1.84, 1.92)
Myocardial Infraction, Nos	7 (0%)	164 (0%)	0.75 (0.36, 1.58)
Non-STEMI	264 (0%)	3,472 (0%)	1.29 (1.14, 1.46)
Palpitations	1,925 (0.2%)	17,754 (0.1%)	1.84 (1.75, 1.93)
STEMI	1,006 (0.1%)	21,499 (0.1%)	0.79 (0.74, 0.84)
<b>2. Gastrointestinal</b>	<b>69,888 (7.7%)</b>	<b>1,283,066 (8.4%)</b>	<b>0.92 (0.91, 0.92)</b>
Acute Abdominal Pain	38,583 (4.3%)	827,028 (5.4%)	0.78 (0.77, 0.79)
Appendicitis	42 (0%)	2,405 (0%)	0.30 (0.22, 0.40)
Blood In Vomit Or Stool (Gi Bleed)	8,032 (0.9%)	58,087 (0.4%)	2.35 (2.30, 2.41)
Bowel Obstruction	216 (0%)	3,044 (0%)	1.20 (1.05, 1.38)
Constipation	2,021 (0.2%)	23,455 (0.2%)	1.46 (1.40, 1.53)
Diarrhea	4,521 (0.5%)	51,130 (0.3%)	1.50 (1.46, 1.55)
Dysphagia	109 (0%)	1,257 (0%)	1.47 (1.21, 1.79)
Esophagitis	372 (0%)	7,850 (0.1%)	0.80 (0.72, 0.89)
Gastroesophageal Reflux Disease (Gerd)	427 (0.1%)	9,663 (0.1%)	0.75 (0.68, 0.82)
Gastrostomy Related	301 (0%)	3,052 (0%)	1.68 (1.49, 1.89)
Hepatic Problem	5,887 (0.7%)	121,454 (0.8%)	0.82 (0.80, 0.84)
Nausea And Vomiting	9,377 (1.0%)	174,641 (1.1%)	0.91 (0.89, 0.93)
<b>3. Endocrine And Electrolyte Abnormalities</b>	<b>14,885 (1.6%)</b>	<b>347,088 (2.3%)</b>	<b>0.72 (0.71, 0.73)</b>
Adrenocortical Insufficiency	9 (0%)	186 (0%)	0.83 (0.43, 1.62)
Diabetic Symptoms, Nos	118 (0%)	3,656 (0%)	0.55 (0.46, 0.66)
Hyperglycemia	5,116 (0.6%)	125,162 (0.8%)	0.69 (0.67, 0.71)
Hyperkalemia	136 (0%)	1,303 (0%)	1.78 (1.50, 2.13)
Hypoglycemia	9,464 (1.0%)	216,299 (1.4%)	0.74 (0.72, 0.75)
Hypokalemia	42 (0%)	482 (0%)	1.48 (1.08, 2.03)
<b>4. Infection</b>	<b>26,215 (2.9%)</b>	<b>311,193 (2.0%)</b>	<b>1.44 (1.42, 1.46)</b>
Carbon Monoxide And Inhalation Exposures	45 (0%)	4,654 (0%)	0.16 (0.12, 0.22)
Cellulitis	2,592 (0.3%)	25,560 (0.2%)	1.72 (1.65, 1.79)
Covid-19 Infection Or Exposure	4,639 (0.5%)	86,545 (0.6%)	0.91 (0.88, 0.93)
Fever	11,039 (1.2%)	126,626 (0.8%)	1.48 (1.45, 1.51)
Sepsis	6,928 (0.8%)	57,197 (0.4%)	2.06 (2.01, 2.11)
Unspecified Infectious Disease	972 (0.1%)	10,611 (0.1%)	1.56 (1.46, 1.66)
<b>5. Injury and Environmental Conditions</b>	<b>136,370 (15.0%)</b>	<b>2,458,143 (16.0%)</b>	<b>0.93 (0.92, 0.93)</b>
Abdomen Injury	261 (0%)	13,892 (0.1%)	0.32 (0.28, 0.36)
Amputation	43 (0%)	1,535 (0%)	0.48 (0.36, 0.65)
Brain Injury	25,876 (2.9%)	334,610 (2.2%)	1.32 (1.30, 1.34)
Burn; Nos	272 (0%)	18,572 (0.1%)	0.25 (0.22, 0.28)
Decompression Sickness	3 (0%)	97 (0%)	0.53 (0.17, 1.66)

## Event-Free Days in OHCA

Page 22 of 24

Drowning	9 (0%)	960 (0%)	0.17 (0.09, 0.32)
Effects Of Air Pressure And Water Pressure	2 (0%)	80 (0%)	0.44 (0.11, 1.74)
Electrocution	20 (0%)	2,930 (0%)	0.12 (0.08, 0.18)
Eye, Ear, Nose, Face Injury	4,524 (0.5%)	97,899 (0.6%)	0.78 (0.76, 0.81)
Foreign Body Injury	691 (0.1%)	17,300 (0.1%)	0.68 (0.63, 0.73)
Frostbite	25 (0%)	978 (0%)	0.45 (0.30, 0.66)
Genitourinary Injury	86 (0%)	1,255 (0%)	1.17 (0.94, 1.46)
Heat Related (Heat Stroke/Exhaustion)	443 (0.1%)	26,827 (0.2%)	0.28 (0.26, 0.31)
Hemorrhage	16,239 (1.8%)	107,576 (0.7%)	2.58 (2.54, 2.63)
Hypothermia	167 (0%)	7,746 (0.1%)	0.37 (0.31, 0.43)
Injury, Unspecified	59,771 (6.6%)	1,304,145 (8.5%)	0.76 (0.75, 0.77)
Lower Back Injury	2,054 (0.2%)	44,826 (0.3%)	0.78 (0.74, 0.81)
Lower Extremity Injuries	17,282 (1.9%)	245,989 (1.6%)	1.19 (1.17, 1.21)
Neck Injury	1,010 (0.1%)	52,294 (0.3%)	0.33 (0.31, 0.35)
Post-Operative Complication	51 (0%)	541 (0%)	1.60 (1.20, 2.13)
Sunburn	4 (0%)	168 (0%)	0.42 (0.16, 1.11)
Thorax Injury	1,046 (0.1%)	28,142 (0.2%)	0.63 (0.59, 0.67)
Upper Extremity Injuries	6,491 (0.7%)	149,781 (1.0%)	0.73 (0.71, 0.75)
<b>6. Kidney/Genitourinary</b>	<b>12,244 (1.4%)</b>	<b>209,106 (1.4%)</b>	<b>0.99 (0.97, 1.01)</b>
Dialysis Problem	47 (0%)	549 (0%)	1.45 (1.08, 1.95)
Displacement Of Urinary Catheter	971 (0.1%)	7,276 (0.1%)	2.26 (2.11, 2.42)
Kidney Stones	377 (0%)	11,049 (0.1%)	1.82 (1.71, 1.93)
Kidney/Renal Disease Requiring Dialysis	1,172 (0.1%)	10,903 (0.1%)	0.58 (0.52, 0.64)
Normal Delivery	12 (0%)	28,300 (0.2%)	0.01 (0.00, 0.01)
Pelvic/Perineal Pain	2,242 (0.3%)	30,756 (0.2%)	1.23 (1.18, 1.29)
Pregnancy Related	34 (0%)	50,475 (0.3%)	0.01 (0.01, 0.02)
Urinary Tract Infection	6,263 (0.7%)	51,391 (0.3%)	2.07 (2.02, 2.13)
Vaginal Bleeding, Abnormal	948 (0.1%)	17,199 (0.1%)	0.93 (0.88, 1.00)
Vascular Dialysis Catheter Problems	178 (0%)	1,208 (0%)	2.50 (2.13, 2.92)
<b>7. Neonatal</b>	<b>9 (0%)</b>	<b>99 (0%)</b>	<b>1.54 (0.78, 3.05)</b>
Congenital Deformity	2 (0%)	24 (0%)	1.49 (0.37, 6.10)
Meconium Aspiration	5 (0%)	38 (0%)	2.32 (0.93, 5.80)
Neonatal Cerebral Depression	0 (0%)	7 (0%)	-
Withdrawal Symptoms From Maternal Substance Abuse	2 (0%)	30 (0%)	1.00 (0.22, 4.52)
<b>8. Neurological</b>	<b>121,213 (13.4%)</b>	<b>2,151,632 (14.0%)</b>	<b>0.95 (0.94, 0.95)</b>
Altered Mental Status And Coma	65,823 (7.3%)	1,096,539 (7.2%)	1.02 (1.01, 1.03)
Headache	7,926 (0.9%)	199,508 (1.3%)	0.67 (0.66, 0.69)
Intracranial Hemorrhage	112 (0%)	854 (0%)	2.22 (1.82, 2.70)
Lightheaded/ Vertigo	15,216 (1.7%)	200,959 (1.3%)	1.29 (1.27, 1.31)
Meningitis And Encephalitis	11 (0%)	335 (0%)	0.56 (0.31, 1.02)
Neurogenic Shock	14 (0%)	305 (0%)	0.80 (0.47, 1.35)
Other Neurologic	192 (0%)	2,883 (0%)	1.13 (0.98, 1.31)
Paralysis	29 (0%)	509 (0%)	0.96 (0.66, 1.40)
Seizures	8,272 (0.9%)	421,009 (2.7%)	0.33 (0.32, 0.33)
Strokes, Tia And Stroke-Like Syndromes	22,971 (2.5%)	220,032 (1.4%)	1.79 (1.76, 1.81)
Visual Disturbance	647 (0.1%)	8,699 (0.1%)	1.26 (1.16, 1.36)
<b>9. Psychiatric</b>	<b>14,977 (1.7%)</b>	<b>864,445 (5.6%)</b>	<b>0.28 (0.28, 0.29)</b>
Anxiety	5,681 (0.6%)	234,857 (1.5%)	0.41 (0.40, 0.42)
Mental Illness, Nos	1,093 (0.1%)	77,629 (0.5%)	0.24 (0.22, 0.25)
Other Personality Disorder	7,382 (0.8%)	484,581 (3.2%)	0.25 (0.25, 0.26)
Suicidal Ideation	445 (0.1%)	29,016 (0.2%)	0.26 (0.24, 0.29)
Suicide Attempt	376 (0%)	38,362 (0.3%)	0.17 (0.15, 0.18)
<b>10. Respiratory And Airway</b>	<b>116,216 (12.8%)</b>	<b>1,244,961 (8.1%)</b>	<b>1.67 (1.65, 1.68)</b>
Acute Epiglottitis	13 (0%)	232 (0%)	0.95 (0.54, 1.66)
Airway Obstruction	67 (0%)	1,358 (0%)	0.85 (0.66, 1.08)
Asphyxia	22 (0%)	1,293 (0%)	0.29 (0.19, 0.44)

## Event-Free Days in OHCA

Page 23 of 24

Asthma, Copd And Bronchospasm	6,567 (0.7%)	114,340 (0.8%)	0.97 (0.95, 1.00)
Atelectasis	5 (0%)	50 (0%)	1.71 (0.68, 4.26)
Bronchitis	539 (0.1%)	7,417 (0.1%)	1.23 (1.13, 1.34)
Carbon Monoxide And Inhalation Exposures	30,102 (3.3%)	277,172 (1.8%)	1.87 (1.84, 1.89)
Cough, Cold, Flu And Other Lung Infections	3,448 (0.4%)	63,460 (0.4%)	0.92 (0.89, 0.95)
Ear, Nose, Throat Problems	6,904 (0.8%)	28,575 (0.2%)	4.11 (4.00, 4.22)
Fluid In Lungs	813 (0.1%)	6,307 (0%)	2.18 (2.03, 2.35)
Laryngitis/Croup	19 (0%)	450 (0%)	0.72 (0.45, 1.13)
Pneumo- And Hemothorax (Traumatic)	67 (0%)	1,921 (0%)	0.59 (0.47, 0.76)
Pneumonia	3,326 (0.4%)	28,481 (0.2%)	1.98 (1.91, 2.05)
Pulmonary Embolism	636 (0.1%)	2,861 (0%)	3.76 (3.45, 4.10)
Pulmonary Hypertension	12 (0%)	90 (0%)	2.35 (1.30, 4.26)
Respiratory Arrest	458 (0.1%)	9,579 (0.1%)	0.81 (0.74, 0.89)
Respiratory Difficulty, Distress, And Failure	58,122 (6.4%)	649,355 (4.2%)	1.55 (1.54, 1.56)
Respiratory, Other Disorder	4,932 (0.5%)	50,111 (0.3%)	1.67 (1.62, 1.72)
Tracheostomy Related	164 (0%)	1,909 (0%)	1.46 (1.24, 1.71)
<b>11. Toxicologic Exposures</b>	<b>7,209 (0.8%)</b>	<b>757,298 (4.9%)</b>	<b>0.15 (0.15, 0.16)</b>
Adverse Effect Of Unspecified Substance	707 (0.1%)	93,172 (0.6%)	0.13 (0.12, 0.14)
Alcohol Use	3,142 (0.4%)	288,068 (1.9%)	0.18 (0.18, 0.19)
Alcohol Withdraw	515 (0.1%)	32,818 (0.2%)	0.27 (0.25, 0.29)
Other Psychoactive Substance	524 (0.1%)	59,229 (0.4%)	0.15 (0.14, 0.16)
Overdose, Nos	1,990 (0.2%)	252,618 (1.7%)	0.13 (0.13, 0.14)
Sedative, Anti-Anxiety Related	114 (0%)	8,630 (0.1%)	0.23 (0.19, 0.27)
Stings/ Venomous Bite	7 (0%)	479 (0%)	0.25 (0.12, 0.53)
Suspected Opioid Related	170 (0%)	19,036 (0.1%)	0.15 (0.13, 0.18)
Venomous Animal Contact	39 (0%)	3,176 (0%)	0.21 (0.16, 0.29)
Venomous Plant Contact	1 (0%)	72 (0%)	0.28 (0.05, 1.71)
<b>12. Other</b>	<b>244,563 (27.0%)</b>	<b>3,781,705 (24.7%)</b>	<b>1.13 (1.12, 1.13)</b>
Adult Or Child General Exam, No Finding	39,147 (4.3%)	907,452 (5.9%)	0.72 (0.71, 0.73)
Allergic Reaction, Nos	1,830 (0.2%)	88,595 (0.6%)	0.35 (0.33, 0.37)
Altitude Sickness	19 (0%)	333 (0%)	1.00 (0.63, 1.58)
Anemia And Bleeding	637 (0.1%)	4,813 (0%)	2.24 (2.06, 2.44)
Back Pain, Nos	20,364 (2.3%)	388,146 (2.5%)	0.89 (0.87, 0.90)
Cancer	634 (0.1%)	9,930 (0.1%)	1.08 (1.00, 1.17)
Dehydration	3,685 (0.4%)	61,598 (0.4%)	1.01 (0.98, 1.05)
Dnr	7 (0%)	139 (0%)	0.86 (0.41, 1.83)
Ear, Nose, Throat Problems	172 (0%)	4,588 (0%)	0.64 (0.55, 0.74)
Edema	4,491 (0.5%)	30,091 (0.2%)	2.54 (2.46, 2.62)
Extremity Pain	9,365 (1.0%)	132,297 (0.9%)	1.20 (1.18, 1.23)
Eye Pain	499 (0.1%)	17,262 (0.1%)	0.49 (0.45, 0.53)
Fatigue	3,775 (0.4%)	59,646 (0.4%)	1.07 (1.04, 1.11)
Flu	963 (0.1%)	20,994 (0.1%)	0.78 (0.73, 0.83)
General Symptoms	2,293 (0.3%)	43,894 (0.3%)	0.88 (0.85, 0.92)
Health Hazard Contact / Suspected Exposure	17 (0%)	1,962 (0%)	0.15 (0.09, 0.24)
Hematoma (Non-Traumatic)	751 (0.1%)	5,358 (0%)	2.38 (2.20, 2.56)
Hemorrhage	13 (0%)	104 (0%)	2.18 (1.23, 3.86)
Hemorrhage, Other	392 (0%)	4,504 (0%)	1.48 (1.33, 1.64)
Medical Device Failure	1,544 (0.2%)	13,301 (0.1%)	1.97 (1.87, 2.07)
Metabolic, Other	199 (0%)	1,962 (0%)	1.73 (1.50, 2.00)
Muscle Weakness	99 (0%)	1,617 (0%)	1.04 (0.85, 1.27)
Musculoskeletal Pain	489 (0.1%)	9,874 (0.1%)	0.84 (0.77, 0.92)
Obesity	44 (0%)	369 (0%)	2.07 (1.52, 2.82)
Obvious Death	5,159 (0.6%)	131,777 (0.9%)	0.66 (0.64, 0.68)
Pain, Acute And Chronic	38,937 (4.3%)	579,243 (3.8%)	1.14 (1.13, 1.16)
Patient Assist And Aftercare	5,908 (0.7%)	75,635 (0.5%)	1.32 (1.29, 1.36)
Septic Shock	477 (0.1%)	4,994 (0%)	1.63 (1.48, 1.79)
Sexual Abuse	32 (0%)	5,028 (0%)	0.11 (0.08, 0.15)
Sickle Cell Crisis	497 (0.1%)	7,102 (0.1%)	1.18 (1.08, 1.30)
Toothache	199 (0%)	8,848 (0.1%)	0.38 (0.33, 0.44)

## Event-Free Days in OHCA

Page **24** of **24**

Weakness	101,925 (11.2%)	1,160,249 (7.6%)	1.55 (1.54, 1.56)
<b>Missing</b>	<b>11,471 (1.3%)</b>	<b>349,372 (2.3%)</b>	



